Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Animal models of multiple sclerosis: From rodents to zebrafish.

Burrows DJ, McGown A, Jain SA, De Felice M, Ramesh TM, Sharrack B, Majid A.

Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246. [Epub ahead of print]

PMID:
30319015
2.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

3.

Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts.

Holden DW, Gold J, Hawkes CH, Giovannoni G, Saxton JM, Carter A, Sharrack B.

Mult Scler Relat Disord. 2018 Oct;25:197-199. doi: 10.1016/j.msard.2018.07.041. Epub 2018 Jul 27.

PMID:
30099206
4.

Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist.

Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, Muraro PA, Lindsay JO.

Clin Med (Lond). 2018 Aug;18(4):329-334. doi: 10.7861/clinmedicine.18-4-329.

PMID:
30072560
5.

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A, Pavitt S, Giovannoni G, Wheeler-Kingshott CAMG, Solanky BS, Weir CJ, Stallard N, Hawkins C, Sharrack B, Chataway J, Connick P, Chandran S; MS-SMART Trialists.

J Neurol. 2018 Aug;265(8):1795-1802. doi: 10.1007/s00415-018-8903-y. Epub 2018 May 30.

6.

Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review.

Manca R, Sharrack B, Paling D, Wilkinson ID, Venneri A.

J Neurol Sci. 2018 May 15;388:115-127. doi: 10.1016/j.jns.2018.03.003. Epub 2018 Mar 2. Review.

PMID:
29627004
7.

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.

Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC; ATX-MS1467 Study Group.

Neurology. 2018 Mar 13;90(11):e955-e962. doi: 10.1212/WNL.0000000000005118. Epub 2018 Feb 21.

PMID:
29467307
8.

Gold nanoparticle-based colorimetric biosensors.

Aldewachi H, Chalati T, Woodroofe MN, Bricklebank N, Sharrack B, Gardiner P.

Nanoscale. 2017 Dec 21;10(1):18-33. doi: 10.1039/c7nr06367a. Review.

PMID:
29211091
9.

Blogs cannot separate wheat from chaff.

Burt RK, Snowden JA, Burman J, Oliveira MC, Sharrack B.

Science. 2017 Nov 3;358(6363):602. doi: 10.1126/science.aar2575. No abstract available.

PMID:
29097540
10.

Qualitative Investigation of Exercise Perceptions and Experiences in People With Multiple Sclerosis Before, During, and After Participation in a Personally Tailored Exercise Program.

Crank H, Carter A, Humphreys L, Snowdon N, Daley A, Woodroofe N, Sharrack B, Petty J, Saxton JM.

Arch Phys Med Rehabil. 2017 Dec;98(12):2520-2525. doi: 10.1016/j.apmr.2017.05.022. Epub 2017 Jun 22.

PMID:
28648682
11.

MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium.

Cerutti C, Edwards LJ, de Vries HE, Sharrack B, Male DK, Romero IA.

Sci Rep. 2017 Mar 30;7:45284. doi: 10.1038/srep45284.

12.

Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.

Waller R, Woodroofe MN, Wharton SB, Ince PG, Francese S, Heath PR, Cudzich-Madry A, Thomas RH, Rounding N, Sharrack B, Simpson JE.

J Neuroimmunol. 2016 Oct 15;299:139-146. doi: 10.1016/j.jneuroim.2016.09.010. Epub 2016 Sep 14.

13.

Autologous hematopoietic cell transplantation in multiple sclerosis.

Bell SM, Sharrack B, Snowden JA.

Expert Opin Biol Ther. 2017 Jan;17(1):77-86. Epub 2016 Oct 14. Review.

14.

Transport of Gold Nanoparticles by Vascular Endothelium from Different Human Tissues.

Gromnicova R, Kaya M, Romero IA, Williams P, Satchell S, Sharrack B, Male D.

PLoS One. 2016 Aug 25;11(8):e0161610. doi: 10.1371/journal.pone.0161610. eCollection 2016.

15.

Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice.

Kelsey PJ, Oliveira MC, Badoglio M, Sharrack B, Farge D, Snowden JA.

Curr Res Transl Med. 2016 Apr-Jun;64(2):71-82. doi: 10.1016/j.retram.2016.03.003. Epub 2016 May 31. Review.

PMID:
27316390
16.

MicroRNA-155 contributes to shear-resistant leukocyte adhesion to human brain endothelium in vitro.

Cerutti C, Soblechero-Martin P, Wu D, Lopez-Ramirez MA, de Vries H, Sharrack B, Male DK, Romero IA.

Fluids Barriers CNS. 2016 May 31;13(1):8. doi: 10.1186/s12987-016-0032-3.

17.

Deficiency in the mRNA export mediator Gle1 impairs Schwann cell development in the zebrafish embryo.

Seytanoglu A, Alsomali NI, Valori CF, McGown A, Kim HR, Ning K, Ramesh T, Sharrack B, Wood JD, Azzouz M.

Neuroscience. 2016 May 13;322:287-97. doi: 10.1016/j.neuroscience.2016.02.039. Epub 2016 Feb 24.

18.

Localization and mobility of glucose-coated gold nanoparticles within the brain.

Gromnicova R, Yilmaz CU, Orhan N, Kaya M, Davies H, Williams P, Romero IA, Sharrack B, Male D.

Nanomedicine (Lond). 2016 Mar;11(6):617-25. doi: 10.2217/nnm.15.215. Epub 2016 Feb 25.

19.

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R.

Lancet Neurol. 2016 Mar;15(3):259-69. doi: 10.1016/S1474-4422(16)00004-1. Epub 2016 Jan 26.

PMID:
26822749
20.

Participant recruitment into a randomised controlled trial of exercise therapy for people with multiple sclerosis.

Carter A, Humphreys L, Snowdon N, Sharrack B, Daley A, Petty J, Woodroofe N, Saxton J.

Trials. 2015 Oct 15;16:468. doi: 10.1186/s13063-015-0996-3.

21.

Cognitive rehabilitation in multiple sclerosis: A systematic review.

Mitolo M, Venneri A, Wilkinson ID, Sharrack B.

J Neurol Sci. 2015 Jul 15;354(1-2):1-9. doi: 10.1016/j.jns.2015.05.004. Epub 2015 May 9. Review.

22.

Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.

Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J.

JAMA. 2015 Jan 20;313(3):275-84. doi: 10.1001/jama.2014.17986.

PMID:
25602998
23.

Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation.

Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, van der Pol SM, Hirst MC, de Vries HE, Sharrack B, Baker D, Male DK, Michael GJ, Romero IA.

J Cereb Blood Flow Metab. 2015 Mar;35(3):412-23. doi: 10.1038/jcbfm.2014.207. Epub 2014 Dec 17.

24.

We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: yes.

Dahdaleh D, Sharrack B.

Mult Scler. 2015 Jan;21(1):35-6. doi: 10.1177/1352458514558678. Epub 2014 Nov 12. No abstract available.

PMID:
25392326
25.

Visual Outcomes from Shunting for Idiopathic Intracranial Hypertension.

Hickman SJ, Raoof N, Panesar H, McMullan JM, Pepper IM, Sharrack B.

Neuroophthalmology. 2014 Nov 12;38(6):310-319. eCollection 2014.

26.

PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy.

Little D, Valori CF, Mutsaers CA, Bennett EJ, Wyles M, Sharrack B, Shaw PJ, Gillingwater TH, Azzouz M, Ning K.

Mol Ther. 2015 Feb;23(2):270-7. doi: 10.1038/mt.2014.209. Epub 2014 Nov 5.

27.

MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation.

Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE, Hirst MC, Sharrack B, Baker D, Male DK, Michael GJ, Romero IA.

FASEB J. 2014 Jun;28(6):2551-65. doi: 10.1096/fj.13-248880. Epub 2014 Mar 6.

PMID:
24604078
28.

Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial.

Tosh J, Dixon S, Carter A, Daley A, Petty J, Roalfe A, Sharrack B, Saxton JM.

Mult Scler. 2014 Jul;20(8):1123-30. doi: 10.1177/1352458513515958. Epub 2014 Jan 13.

PMID:
24421304
29.

Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial.

Carter A, Daley A, Humphreys L, Snowdon N, Woodroofe N, Petty J, Roalfe A, Tosh J, Sharrack B, Saxton JM.

Mult Scler. 2014 Jul;20(8):1112-22. doi: 10.1177/1352458513519354. Epub 2014 Jan 13.

PMID:
24421303
30.

Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension.

Edwards LJ, Sharrack B, Ismail A, Tench CR, Gran B, Dhungana S, Brettschneider J, Tumani H, Constantinescu CS.

Am J Clin Exp Immunol. 2013 Oct 16;2(3):234-44. eCollection 2013.

31.

Cytokine-induced changes in the gene expression profile of a human cerebral microvascular endothelial cell-line, hCMEC/D3.

Lopez-Ramirez MA, Male DK, Wang C, Sharrack B, Wu D, Romero IA.

Fluids Barriers CNS. 2013 Sep 19;10(1):27. doi: 10.1186/2045-8118-10-27.

32.

Pragmatic exercise intervention in people with mild to moderate multiple sclerosis: a randomised controlled feasibility study.

Carter AM, Daley AJ, Kesterton SW, Woodroofe NM, Saxton JM, Sharrack B.

Contemp Clin Trials. 2013 Jul;35(2):40-7. doi: 10.1016/j.cct.2013.04.003. Epub 2013 Apr 21.

PMID:
23612222
33.

A genetic study of Wilson's disease in the United Kingdom.

Coffey AJ, Durkie M, Hague S, McLay K, Emmerson J, Lo C, Klaffke S, Joyce CJ, Dhawan A, Hadzic N, Mieli-Vergani G, Kirk R, Elizabeth Allen K, Nicholl D, Wong S, Griffiths W, Smithson S, Giffin N, Taha A, Connolly S, Gillett GT, Tanner S, Bonham J, Sharrack B, Palotie A, Rattray M, Dalton A, Bandmann O.

Brain. 2013 May;136(Pt 5):1476-87. doi: 10.1093/brain/awt035. Epub 2013 Mar 21.

34.

Wegener's granulomatosis presenting with multiple cranial nerve palsies and pachymeningitis.

Iqbal AM, Blackburn D, Rafiq M, Sharrack B.

Pract Neurol. 2013 Jun;13(3):193-5. doi: 10.1136/practneurol-2012-000340. Epub 2013 Mar 13. No abstract available.

PMID:
23487806
35.

Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis.

Alix JJ, Blackburn DJ, Sokhi D, Craven I, Sharrack B, Snowden JA.

J Neurol. 2013 Mar;260(3):914-6. doi: 10.1007/s00415-012-6796-8. Epub 2012 Dec 27. No abstract available.

PMID:
23269440
36.

Pragmatic exercise intervention for people with multiple sclerosis (ExIMS trial): study protocol for a randomised controlled trial.

Saxton JM, Carter A, Daley AJ, Snowdon N, Woodroofe MN, Petty J, Roalfe A, Tosh J, Sharrack B.

Contemp Clin Trials. 2013 Mar;34(2):205-11. doi: 10.1016/j.cct.2012.10.011. Epub 2012 Nov 1.

PMID:
23123791
37.

Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72.

Ismail A, Cooper-Knock J, Highley JR, Milano A, Kirby J, Goodall E, Lowe J, Scott I, Constantinescu CS, Walters SJ, Price S, McDermott CJ, Sawcer S, Compston DA, Sharrack B, Shaw PJ.

J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):79-87. doi: 10.1136/jnnp-2012-303326. Epub 2012 Oct 20.

PMID:
23085936
38.

Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells.

Lopez-Ramirez MA, Fischer R, Torres-Badillo CC, Davies HA, Logan K, Pfizenmaier K, Male DK, Sharrack B, Romero IA.

J Immunol. 2012 Sep 15;189(6):3130-9. doi: 10.4049/jimmunol.1103460. Epub 2012 Aug 15.

39.

siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line.

Hurst LA, Bunning RA, Sharrack B, Woodroofe MN.

Neurosci Lett. 2012 Jul 11;521(1):52-6. doi: 10.1016/j.neulet.2012.05.057. Epub 2012 May 26.

PMID:
22641052
40.

Isolation of enriched glial populations from post-mortem human CNS material by immuno-laser capture microdissection.

Waller R, Woodroofe MN, Francese S, Heath PR, Wharton SB, Ince PG, Sharrack B, Simpson JE.

J Neurosci Methods. 2012 Jul 15;208(2):108-13. doi: 10.1016/j.jneumeth.2012.04.014. Epub 2012 Apr 26.

PMID:
22609336
41.

The cost of long hospital stays.

Jenkins TM, Sharrack B.

Clin Med (Lond). 2012 Feb;12(1):98-9. No abstract available.

PMID:
22372241
42.

CCL2 binding is CCR2 independent in primary adult human astrocytes.

Fouillet A, Mawson J, Suliman O, Sharrack B, Romero IA, Woodroofe MN.

Brain Res. 2012 Feb 9;1437:115-26. doi: 10.1016/j.brainres.2011.11.049. Epub 2011 Dec 4.

PMID:
22226505
43.

Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial.

Cooper CL, Hind D, Parry GD, Isaac CL, Dimairo M, O'Cathain A, Rose A, Freeman JV, Martin L, Kaltenthaler EC, Thake A, Sharrack B.

Trials. 2011 Dec 14;12:259. doi: 10.1186/1745-6215-12-259.

44.

Adversarial growth in patients with multiple sclerosis and their partners: relationships with illness perceptions, disability and distress.

Ackroyd K, Fortune DG, Price S, Howell S, Sharrack B, Isaac CL.

J Clin Psychol Med Settings. 2011 Dec;18(4):372-9. doi: 10.1007/s10880-011-9265-0.

PMID:
21986996
45.

Multiple sclerosis in an adrenoleukodystrophy carrier.

Jenkins T, Sarasamma P, Gillett G, Coley S, Sharrack B.

Clin Pract. 2011 Nov 30;1(4):e125. doi: 10.4081/cp.2011.e125. eCollection 2011 Sep 28.

46.

Early diagnosis of Horner syndrome using topical apraclonidine.

Cooper-Knock J, Pepper I, Hodgson T, Sharrack B.

J Neuroophthalmol. 2011 Sep;31(3):214-6. doi: 10.1097/WNO.0b013e31821a91fe.

PMID:
21566530
47.

Central inflammation versus peripheral regulation in multiple sclerosis.

Edwards LJ, Sharrack B, Ismail A, Tumani H, Constantinescu CS.

J Neurol. 2011 Aug;258(8):1518-27. doi: 10.1007/s00415-011-5973-5. Epub 2011 Mar 9.

PMID:
21547381
48.

The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK.

Raoof N, Sharrack B, Pepper IM, Hickman SJ.

Eur J Neurol. 2011 Oct;18(10):1266-8. doi: 10.1111/j.1468-1331.2011.03372.x. Epub 2011 Mar 22. Review.

PMID:
21426442
49.

Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis.

Kirby J, Ning K, Ferraiuolo L, Heath PR, Ismail A, Kuo SW, Valori CF, Cox L, Sharrack B, Wharton SB, Ince PG, Shaw PJ, Azzouz M.

Brain. 2011 Feb;134(Pt 2):506-17. doi: 10.1093/brain/awq345. Epub 2011 Jan 12.

50.

A randomised controlled trial of treatment for idiopathic intracranial hypertension.

Ball AK, Howman A, Wheatley K, Burdon MA, Matthews T, Jacks AS, Lawden M, Sivaguru A, Furmston A, Howell S, Sharrack B, Davies MB, Sinclair AJ, Clarke CE.

J Neurol. 2011 May;258(5):874-81. doi: 10.1007/s00415-010-5861-4. Epub 2010 Dec 16.

PMID:
21161260

Supplemental Content

Loading ...
Support Center